Which has higher earnings and valuation, HBP or RVX?

Helix BioPharma is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Helix BioPharma N/A N/A -C$50.55M -C$0.06 N/A Resverlogix N/A N/A -C$2.81M -C$0.03 N/A

Is HBP or RVX more profitable?

Resverlogix's return on equity of 6.67% beat Helix BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Helix BioPharma N/A -36.79% -279.98% Resverlogix N/A 6.67% -34.90%

Which has higher earnings and valuation, SCYB or RVX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scythian Biosciences N/A N/A N/A N/A N/A Resverlogix N/A N/A -C$2.81M -C$0.03 N/A

Is SCYB or RVX more profitable?

Resverlogix's return on equity of 6.67% beat Scythian Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Scythian Biosciences N/A N/A N/A Resverlogix N/A 6.67% -34.90%

Which has better earnings & valuation, COM or RVX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 138267 (COM.TO) N/A N/A N/A N/A N/A Resverlogix N/A N/A -C$2.81M -C$0.03 N/A

Is COM or RVX more profitable?

Resverlogix's return on equity of 6.67% beat 138267 (COM.TO)'s return on equity. Company Net Margins Return on Equity Return on Assets 138267 (COM.TO) N/A N/A N/A Resverlogix N/A 6.67% -34.90%

Is NVH or RVX more profitable?

Resverlogix's return on equity of 6.67% beat Novoheart's return on equity. Company Net Margins Return on Equity Return on Assets Novoheart N/A N/A N/A Resverlogix N/A 6.67% -34.90%

Is RVX or IGX more profitable?

Resverlogix's return on equity of 6.67% beat IntelGenx Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Resverlogix N/A 6.67% -34.90% IntelGenx Technologies N/A N/A N/A

Resverlogix (RVX) Competitors

C$0.10 0.00 (0.00%)

As of 06/12/2026

Compare

RVX vs. HBP, SCYB, COM, NVH, and IGX

Should you buy Resverlogix stock or one of its competitors? MarketBeat compares Resverlogix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Resverlogix include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Helix BioPharma had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Resverlogix. Helix BioPharma's average media sentiment score of 1.08 beat Resverlogix's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Helix BioPharma	Positive
Resverlogix	Neutral

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.0% of Resverlogix shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Helix BioPharma is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helix BioPharma	N/A	N/A	-C$50.55M	-C$0.06	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

Helix BioPharma has a beta of 0.421776, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Resverlogix has a beta of 0.260846, meaning that its stock price is 74% less volatile than the broader market.

Resverlogix's return on equity of 6.67% beat Helix BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Helix BioPharma	N/A	-36.79%	-279.98%
Resverlogix	N/A	6.67%	-34.90%

Summary

Resverlogix beats Helix BioPharma on 7 of the 10 factors compared between the two stocks.

How does Resverlogix compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
Scythian Biosciences	Neutral
Resverlogix	Neutral

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Resverlogix's return on equity of 6.67% beat Scythian Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scythian Biosciences	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scythian Biosciences	N/A	N/A	N/A	N/A	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

Summary

Resverlogix beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
138267 (COM.TO)	Neutral
Resverlogix	Neutral

Resverlogix's return on equity of 6.67% beat 138267 (COM.TO)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

Summary

Resverlogix beats 138267 (COM.TO) on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Novoheart (CVE:NVH) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Novoheart's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
Novoheart	Neutral
Resverlogix	Neutral

Resverlogix has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novoheart	C$423.50K	236.08	-C$7.17M	-C$0.04	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

Resverlogix's return on equity of 6.67% beat Novoheart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novoheart	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Resverlogix beats Novoheart on 6 of the 8 factors compared between the two stocks.

How does Resverlogix compare to IntelGenx Technologies?

Resverlogix (TSE:RVX) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Resverlogix has higher earnings, but lower revenue than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A
IntelGenx Technologies	C$1.75M	49.95	-C$11.74M	-C$0.08	N/A

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Resverlogix's average media sentiment score of 0.00 equaled IntelGenx Technologies'average media sentiment score.

Company	Overall Sentiment
Resverlogix	Neutral
IntelGenx Technologies	Neutral

Resverlogix's return on equity of 6.67% beat IntelGenx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Resverlogix	N/A	6.67%	-34.90%
IntelGenx Technologies	N/A	N/A	N/A

Summary

Resverlogix beats IntelGenx Technologies on 6 of the 8 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVX vs. The Competition

Export

Metric	Resverlogix	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$31.70M	C$445.63M	C$6.52B	C$12.19B
Dividend Yield	7.02%	3.88%	2.67%	6.19%
P/E Ratio	-3.33	3.19	24.00	36.94
Price / Sales	N/A	6,464.11	514.36	10.45
Price / Cash	132.50	13.13	27.48	82.29
Price / Book	-0.33	86.75	10.54	4.47
Net Income	-C$2.81M	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	N/A	0.09%	0.60%	0.65%
1 Month Performance	N/A	-0.27%	1.56%	-0.08%
1 Year Performance	N/A	56.11%	25.42%	41.90%

Resverlogix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVX Resverlogix	N/A	C$0.10 flat	N/A	N/A	C$31.70M	N/A	N/A	19
HBP Helix BioPharma	N/A	C$1.53 -3.2%	N/A	N/A	C$116.86M	N/A	N/A	9	Earnings Report Gap Down
SCYB Scythian Biosciences	N/A	C$3.49 -5.9%	N/A	+0.0%	C$102.38M	N/A	N/A	N/A	High Trading Volume
COM 138267 (COM.TO)	N/A	N/A	N/A	N/A	C$102.19M	N/A	N/A	N/A
NVH Novoheart	N/A	C$0.53 +1.9%	N/A	+0.0%	C$99.98M	C$423.50K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Resverlogix (RVX) Competitors

RVX vs. HBP, SCYB, COM, NVH, and IGX

How does Resverlogix compare to Helix BioPharma?

Summary

How does Resverlogix compare to Scythian Biosciences?

Summary

How does Resverlogix compare to 138267 (COM.TO)?

Summary

How does Resverlogix compare to Novoheart?

Summary

How does Resverlogix compare to IntelGenx Technologies?

Summary

Media Sentiment Over Time

RVX vs. The Competition

Resverlogix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Resverlogix (RVX) Competitors

RVX vs. HBP, SCYB, COM, NVH, and IGX

How does Resverlogix compare to Helix BioPharma?

Does the media favor HBP or RVX?

Do institutionals & insiders have more ownership in HBP or RVX?

Which has higher earnings and valuation, HBP or RVX?

Which has more volatility & risk, HBP or RVX?

Is HBP or RVX more profitable?

Summary

How does Resverlogix compare to Scythian Biosciences?

Does the media refer more to SCYB or RVX?

Do institutionals & insiders have more ownership in SCYB or RVX?

Is SCYB or RVX more profitable?

Which has higher earnings and valuation, SCYB or RVX?

Summary

How does Resverlogix compare to 138267 (COM.TO)?

Which has better earnings & valuation, COM or RVX?

Do insiders & institutionals have more ownership in COM or RVX?

Does the media favor COM or RVX?

Is COM or RVX more profitable?

Summary

How does Resverlogix compare to Novoheart?

Does the media favor NVH or RVX?

Which has higher valuation and earnings, NVH or RVX?

Is NVH or RVX more profitable?

Do institutionals and insiders hold more shares of NVH or RVX?

Summary

How does Resverlogix compare to IntelGenx Technologies?

Which has stronger earnings & valuation, RVX or IGX?

Do insiders and institutionals hold more shares of RVX or IGX?

Does the media refer more to RVX or IGX?

Is RVX or IGX more profitable?

Summary

Media Sentiment Over Time

RVX vs. The Competition

Resverlogix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools